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Tetrazine Responsive Self-Immolative Linkers 
Kevin Neumann, Sarthak Jain, Alessia Gambardella, Sarah E. Walker, Elsa Valero, Annamaria 
Lilienkampf and Mark Bradley*[a] 
 
Abstract: Molecules that undergo activation or modulation following 
the addition of benign external small molecule chemical stimuli have 
numerous applications. Here, we report the highly efficient “decaging” 
of a variety of moieties by activation of a “self-immolative” linker by 
application of a water soluble and stable tetrazine, including the 
controlled delivery of Doxorubicin in a cellular context. 
Stimuli responsive compounds that undergo molecular 
modulation, activation or that switch on a desired physical, 
chemical or biological function upon the addition of an external 
chemical or physical trigger such as pH, temperature or light, 
have enormous power and biomedical potential.[1],[2] Light in 
particular has been used, as a stimulus, for various applications 
ranging from polymers containing azobenzene units that 
undergo reversible cis/trans photoisomerisation resulting in 
controllable polymer modulation,[3] to nanoparticles that 
reversibly contract (150 to 40 nm) upon photo-triggering and 
light-mediated antibody activation.[4] Numerous polymer 
architectures have been generated where pH can reversibly 
alter polymer topography by changes in protonation state,[5] or 
irreversibly via bond cleavage (resulting in cargo liberation).[6],[7] 
 Many chemical moieties have been developed that 
respond to a range of molecular triggers. For example, boronate 
functionalised polymers have been designed to react with 
glucose thereby mediating insulin release[8] and hydrogels that 
respond to the presence of specific antigens via swelling and 
cargo liberation have been synthesised.[9] Li reported the caging 
of the catalytic lysine residue in OspF with a 
propargyloxycarbonyl group, which was cleaved by Pd catalysis 
switching on the protein function.[10] A key feature of many of 
these activation systems is the integration of a “self-immolative 
safety-catch”[11] type linker, whereby remote functional group 
activation leads to subsequent 1,6-elimination and target/cargo 
liberation. This includes the work of Urano who used 500 nm 
light to liberate BODIPY-caged histamine[12] whereas Springer 
applied this approach to generate carboxypeptidase activated 
prodrugs of Doxorubicin (Dox).[13] Numerous other examples 
exist where the 1,6-elimination process has been used as a 
response to a variety of analytes and redox states leading to 
polymer “depolymerisation”.[14],[15],[16] Even though these triggers 
and materials show huge potential there are still major 
challenges, including problems associated with light stimulated 
materials due to high tissue absorbance, neurotoxicity for 
common acrylate and acrylamide-based thermally responsive 
materials,[17] and the lack of tissue specificity with respect to pH. 
 Tetrazines have recently been exploited in a variety of 
inverse electron-demand Diels–Alder reactions (DAINV) as a 
means of conjugating reporters (e.g. fluorophores[18],[19],[20] and 
PET isotopes[21],[22]) to a variety of biological entities such as 
DNA,[23] targeting peptides,[24] and antibodies.[25],[26] Typically, 
these bioconjugations are performed between a tetrazine and 
strained dienophile, such as trans-cyclooctene (TCO), resulting 
in a fast DAINV reaction.[27] Thus Chen developed bioorthogonal 
protein activation chemistry, with protection of the catalytic lysine 
residue in firefly luciferase with TCO rendering the protein 
inactive and treatment with a tetrazine restoring the protein 
function.[28] Tetrazine ligation with TCO has also been utilised for 
prodrug activation using Doxorubicin conjugated via a 
carbamate linkage to the allylic position of TCO, with DAINV 
liberating the free drug.[29]  
 In addition to the widely applied reactivity with strained 
alkenes and alkynes, tetrazines have been shown to rapidly 
react with cyclopentanone morpholine enamines and N-vinyl 
pyrrolidinones to liberate amines and amides, respectively.[30] 
Recently, it was shown that tetrazines react with phenyl vinyl 
ethers resulting in liberation of a phenol moiety.[31] This reactivity 
directed our attention to the application of tetrazines not only in 
the decaging of phenols but also to 1,6-elimination chemistry via 
a self-immolative linker approach. Herein, we demonstrate the 
selective release of both  
Figure 1. a) Nanoparticles with an average diameter of 35 nm were 
fabricated from the amphiphilic block-co-polymer PEG-b-Dox, with the 
methacrylate–Doxorubicin conjugated segment forming the hydrophobic core. 
Upon reaction with tetrazine, doxorubicin (red spheres) is liberated, driven by 
the 1,6-elimination reaction of the self-immolative linker. b) The mechanism 
of tetrazine mediated vinyl ether decaging and cargo liberation (here RNH2). 
[a] Kevin Neumann, Sarthak Jain, Alessia Gambardella, Dr. Sarah E. 
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caged fluorophores and the anticancer drug Doxorubicin by a 
tetrazine-mediated vinyl ether based dienophile, which upon a 
reaction with a DAINV reaction (Figure 1). The designed system 
comprised a tetrazine (the stimulus) decages a phenol(ate) 
prompting the subsequent release of Doxorubicin via 1,6-
elimination. Additional functionalisation of the linker with a 
methacrylate allowed the formation of amphiphilic PEG-b-Dox 
co-polymer nanoparticles that, upon reaction with tetrazine, 
released Doxorubicin resulting in the “switch-on” of cytotoxicity. 
In the absence of the stimulus, these PEG-b-Dox nanoparticles 
have low cytotoxicity and therefore have the potential to improve 
drug efficacy. Vinyl groups have been shown to be good 
dienophiles in DAINV reactions and have been used to efficiently 
label and subsequently image 5-vinyl-2’-deoxyuridine modified 
DNA.[32] Our hypothesis was that vinyl ethers could act as 
masking groups for phenols and that tetrazine-mediated 
activation via the incorporation of a self-immolative liker would 
allow the “switch-on” of fluorophores as well as enabling 
targeted drug release. The phenolic groups of fluorescein 1 and 
resorufin 2 were readily converted to vinyl ethers using the vinyl 
boronic anhydride pyridine complex reported by O’Shea[33] to 
give the quenched fluorophores bis-O-vinyl fluorescein 3 and O-
vinyl resorufin 4 (Figure S1–S2). Incubation with dipyridyl 
tetrazine 5 allowed efficient removal of the vinyl groups via the 
DAINV with the reaction being readily monitored by 1H NMR and 
regeneration of fluorescence, giving a 23-fold increase in 
fluorescence with bis-O-vinyl fluorescein 3 and 99-fold increase 
with O-vinyl resorufin 4 (Figure 2, Figure S3–S4).  
 To broaden this approach, a tetrazine responsive self-
immolative linker was designed consisting of a 4-hydroxymethyl 
phenyl vinyl ether scaffold, thereby allowing cargo conjugation 
(such as fluorophores or drugs) via carbamate formation, 
Figure 2. a) Tetrazine 5 triggered decaging of bis-O-vinyl fluorescein 3 and O-
vinyl resorufin 4 at 37 °C in PBS (pH 7.4) led to fluorescence “switch on”. b) 
DAINV reaction between tetrazine 5 (200 µM) and 4 (35 µM) led to a 99-fold 
increase in fluorescence (λEx/Em 530/590 nm) whereas the same reaction with 3 
(35 µM) led to a 23-fold increase (λEx/Em 485/528 nm). c) Monitoring of the 
reaction between bis-O-vinyl fluorescein 3 and tetrazine S1 (See Figure S5) in 
DMSO by 1H NMR showed the initial formation of the mono O-vinyl fluorescein 
with full conversion to 1 after 48 h at 37 °C. 
with remote activation (based on a 1,6-elimination reaction) 
following liberation of the phenolate by the tetrazine-mediated 
removal of the vinyl ether group (Figure 1b). Furthermore, the 
phenyl ring contained a C3 spacer linked to a methacrylate 
moiety for polymerisation chemistries. The tetrazine responsive 
self-immolative linker 6 was synthesised by selective para 
tetrahydropyranyl (THP) ether protection of 2,4-
dihydroxybenzaldehyde 7 (to give compound 8) and subsequent 
ortho etherification using 3-bromopropyl methacrylate to give 9 
(Figure 3a). Following THP deprotection, vinylation of the free 
phenol was achieved using the vinyl boronic anhydride pyridine 
complex[31] as described above. Finally, aldehyde 10 was 
reduced with NaBH4 and the resulting linker 6 transformed into 
the nitrophenyl activated carbonate 11. Nile Blue was coupled to 
the linker to give the Nile Blue carbamate 12 with quenched 
fluorescence (Figure 3b), which upon reaction with tetrazine 5 
under aqueous conditions underwent vinyl group removal with 
subsequent 1,6-elimination, loss of CO2 and switch-on of 
fluorescence of Nile Blue 13 (Figure 3, Figure S6).  
To further demonstrate the potential of external small-molecule 
controlled cargo release, the activated linker 11 was conjugated 
to the anti-cancer agent Doxorubicin (Figure 4a), a DNA 
interchelating anthracycline antibiotic used for the treatment of 
malignancies including breast and ovarian tumours, sarcomas, 
and acute leukemias.[34] The Doxorubicin monomer 14 showed 
>90% conversion to the free drug after 5 day incubation with 
tetrazine 5 (Figure 4b). The methacrylate moiety of 14 was  
Figure 3. Synthesis and activation of the tetrazine cleaved self-immolative 
linker. a) i) 2,4-Dihydro-2H-pyran, PPTS, DCM, 60 %; ii) 3-Bromopropyl 
methacrylate, Cs2CO3, DMF, 50 °C, 77 %; iii) (1) 1M HCl (aq.), MeOH, (2) 
Cs2CO3, vinyl boronic anhydride pyridine complex, Cu(OAc)2, DCM, 55 %; iv) 
NaBH4, MeOH, quant.; v) Phenylchloroformate, Et3N, 83 %.; vi) Nile Blue 13, 
Et3N, DCM/THF, rt, 16 %; vii) DAINV of 12 (40 µM) and tetrazine 5 (100 µM) led 
to an 8-fold increase in fluorescence in PBS (pH 7.4) at 37 °C (see Figure S6). 
b) Fluorescence spectra of Nile Blue 13 and the fully quenched Nile Blue 
carbamate 12 (λEx/Em 590/645 nm). 
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Figure 4. Synthesis and characterisation of Doxorubicin conjugated 
nanoparticles (PEG-b-Dox). a) i) Doxorubicin hydrochloride, Et3N, 51 %; ii) 
PEG CTA, APS, TMEDA, DMSO, 30 °C. b) Release profile of Dox from 
monomer 14 (2.3 mM) by tetrazine 5 (23 mM) at 37 °C in PBS/ACN as 
monitored by HPLC (λAbs 495 nm). c) Size analysis (by dynamic light 
scattering) of the PEG-b-Dox derived nanoparticles showing an average 
diameter of 35 nm in PBS (pH 7.4) at 37 °C. 
polymerised with the RAFT reagent PEG CTA (Mn 10,000 g mol-
1) using APS/TMEDA as the redox initiator to give the 
amphiphilic PEG-b-Dox co-polymer 15 (Mn 13,000 g mol-1). 
These mild reaction conditions were required as thermally or UV 
initiated polymerisations led to co-reaction of the vinyl ether 
groups. Once placed in water, the PEG-b-Dox co-polymer 15 
formed nanoparticles with a diameter of 35 nm (Figure 4c, 
Figure 5. Tetrazine triggered release of Doxorubicin. HEK273T cells were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10 % FBS. Nanoparticles, tetrazine 5 and/or free Doxorubicin were incubated 
with cells at 37 °C with 5 % CO2 for 48 h. a) Control (just cells); b) PEG-b-Dox 
15 nanoparticles (1 µM equiv. of Dox); c) Tetrazine 5 (35 µM); d) Tetrazine 5 
(35 µM) and PEG-b-Dox 15 nanoparticles (1 µM). The samples were stained 
with propidium iodide (2 µM) and analysed by flow cytometry (λEx 488 nm with 
500–554 nm broad pass filter). Forward versus side scatter (SSC-A) profiles 
were used to gate intact cellular materials and determine membrane integrity 
(PI).  
Figure S7), with the hydrophobic core of each particle, 
consisting of four Doxorubicin units (determined by 1H NMR) 
linked to the methacrylate backbone, surrounded by a 
hydrophilic PEG shell.  
Tetrazine-mediated controlled drug release was explored using 
HEK273T cells. The PEG-b-Dox nanoparticles (loading 
equivalent to 8 µM of Dox) showed no cytotoxicity after 48 h 
(MTT assay), whereas 1 µM “free” Doxorubicin resulted in 
complete cell death (Figure S8–S9). Tetrazine 5 showed no 
toxicity at a concentration of 35 µM. When the cells were treated 
with 1 µM PEG-b-Dox nanoparticles (equivalent to 4 µM of Dox), 
the addition of tetrazine 5 (35 µM) triggered cytotoxicity with 
80 % cell death after 48 h incubation (Figure 5, Figure S10). 
Comparable results were obtained with prostate cancer cell line 
PC3, with cytotoxicity of PEG-b-Dox triggered only in 
combination with tetrazine (Figure S10). This indicates that the 
nanoparticles underwent efficient tetrazine triggering, even in a 
complex cellular environment, leading to a controlled switch-on 
of cytotoxicity. 
 
In summary, we have demonstrated the practicality and 
application of a tetrazine-activated self-immolative linker, which 
allows the controlled release of fluorophores and drugs within a 
complex biological milieu. Nanoparticles containing multiple 
covalently attached Doxorubicins (attached via a 4-
hydroxymethyl phenyl vinyl ether linker) demonstrated efficient 
tetrazine-mediated switch-on of cytotoxicity via 1,6-elimination 
driven release. In the absence of a tetrazine stimulus, the PEG-
b-Dox nanoparticles display low cytotoxicity and inherently have 
EPR targeting abilities. This novel approach offers new 
opportunities in the field of targeted and controlled drug delivery 
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